salivary gland neoplasms/braken

De link wordt op het klembord opgeslagen

LidwoordKlinische proevenOctrooien

Kies het sorteertype

6 resultaten

Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Salivary gland cancers (SGCs) are uncommon and account for less than 5% of all head and neck cancers, but they are histologically heterogeneous. No specific therapy, including targeted agents, has consistently improved clinical outcomes in recurrent/metastatic SGC. Recent studies suggest that

Preliminary experience with chemotherapy in advanced salivary gland neoplasms.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Eight patients with advanced incurable salivary gland carcinoma were treated with the combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). There were three clinical complete responses and two excellent partial responses. One of the three nonresponders had symptomatic improvement

Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical

Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Some previous studies have shown that vinorelbine (VNB) is active in recurrent salivary gland tumors. METHODS Between April 1993 and April 1997, 36 patients in a Phase II randomized trial received either cisplatin, 80 mg/m(2), on Day 1 plus VNB, 25 mg/m(2), on Days 1 and 8 (every 3 weeks)

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT. We conducted a phase II study to

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+),

Word lid van onze
facebookpagina

Herbal & Natural Medicine

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

Werkt in 55 talen
Kruidengeneesmiddelen gesteund door de wetenschap
Kruidenherkenning door beeld
Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
Zoek medicinale kruiden op hun effecten
Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek